Back to search

Article

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

2021-03-10

Abstract excerpt

<title>Abstract</title> <p>Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i), combined with endocrine therapy (ET), have demonstrated higher antitumor activity than ET alone for the treatment of advanced estrogen receptor-positive (ER+) breast cancer (BC). Some ER+ BC are de novo resistant to CDK4/6i and others develop acquired resistance. Therapies for tumors after progression are needed. Here, we demonstrat...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
3aac2d1b-0df5-562d-a2da-a914df1afd8a
DOI
10.21203/rs.3.rs-236645/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancerDOI 10.21203/rs.3.rs-236645/v1
The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancerSemantic proximity
Genomic and Transcriptomic Determinants of Resistance to CDK4/6 Inhibitors and Response to Combined Exemestane plus Everolimus and Palbociclib in Patients with Metastatic Hormone Receptor Positive Breast CancerSemantic proximity
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast CancerSemantic proximity
Impact of homologous recombination deficiency on CDK4/6 inhibitor sensitivity in HR+/HER2-breast cancerSemantic proximity
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trialSemantic proximity
Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical PracticeSemantic proximity
A comprehensive luminal breast cancer patient‐derived xenografts ( PDX ) library to capture tumor heterogeneity and explore the mechanisms of resistance to CDK4 /6 inhibitorsSemantic proximity
Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunitiesSemantic proximity
Reversal of endocrine resistance via N6AMT1-NEDD4L pathway-mediated p110α degradationSemantic proximity
Genomic alterations associated with resistance and circulating tumor DNA dynamics for early detection of progression on CDK4/6 inhibitor in advanced breast cancer.Semantic proximity
Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.Semantic proximity
Acquired resistance to CDK4/6 inhibition is associated with dysregulation of multiple pathways including cyclin D-CDK4/6-RB, EGFR/HER, AKT/mTOR and IFN signalingSemantic proximity
Select a neighboring publication to make it the new centre.